{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_bundle","feature":"bundle","name":"LLM article bundle","what":"Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.","contains":"body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest","slug":"pt-141-chemo","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-chemo/bundle?format=markdown"},"how_to_use":"Reference bundle for an LLM or reader. §SELF explains the surface; ingest and claim endpoints in llm_manifest are the write-back routes.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/pt-141-chemo/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-chemo/topology"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-chemo/voxels","write":"https://miscsubjects.com/api/protocol/claim"}},{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-chemo/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"ingest","name":"Ingest protocol","what":"Parse pasted evidence → source ledger + claims + evidence_ingest node.","urls":{"write":"https://miscsubjects.com/api/protocol/ingest"}},{"id":"claim_post","name":"Claim post protocol","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-chemo/voxels","write":"https://miscsubjects.com/api/protocol/claim"}},{"id":"llm_manifest","name":"LLM manifest","what":"Machine-readable read/write contract for external LLMs.","urls":{"read":"https://miscsubjects.com/api/articles/llm-manifest"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"bundle","name":"LLM article bundle","what":"Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.","why":"Every feature is auditable collective intelligence","how":"Reference bundle for an LLM or reader. §SELF explains the surface; ingest and claim endpoints in llm_manifest are the write-back routes.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/pt-141-chemo/bundle?format=markdown"},"imessage":null,"router":null,"related":[{"id":"topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."},{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"ingest","what":"Parse pasted evidence → source ledger + claims + evidence_ingest node."},{"id":"claim_post","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by."},{"id":"llm_manifest","what":"Machine-readable read/write contract for external LLMs."}],"not_medical_advice":true},"MASTHEAD":{"sorry_status":"planes not merged yet — sorry-status activates after voxel-merge-planes","identity":{"slug":"pt-141-chemo","version":2,"content_hash":"09668f6bb422979192f712536034b6e0638e48794f6b0490708f73c4ee144fb5","thread_head":"genesis","divs":28},"thesis":{"root_claim":"c1","text":"Two phase 3 randomized trials showed bremelanotide improved desire scores versus placebo in premenopausal women with HSDD.","tier":"human"},"load_bearing":[{"id":"c2","tier":"human","status":"active","text":"No published randomized trials study bremelanotide in cancer survivors or chemotherapy patients."},{"id":"c4","tier":"human","status":"active","text":"One randomized trial found pregabalin superior to gabapentin for cancer-related neuropathic pain on VAS scores and opioid use."},{"id":"c3","tier":"mechanistic","status":"active","text":"PT-141 acts via melanocortin receptor agonism in central pathways linked to sexual motivation."},{"id":"c5","tier":"anecdotal","status":"active","text":"Reddit and X mentions of PT-141 with chemotherapy are sparse personal accounts without controlled verification."}],"standing_objections":{"open":0,"strongest_open":null,"link":"https://miscsubjects.com/api/articles/pt-141-chemo/discourse"},"verbs":{"read":"GET https://miscsubjects.com/api/articles/pt-141-chemo/voxels — DIVs + hashes + chains (free)","read_claims":"GET https://miscsubjects.com/api/articles/pt-141-chemo/claims — every formal claim as claim:<id> with current hash, thread, stable link, and exact contribution/edit bodies","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {slug, expected_thread_head, target_div?, expected_hash?, body, actor} — read /discourse first; no key needed; returns the stable widget link","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {slug, outcome, content_hash, actor} — close your read with one of four outcomes","mutate":"voxel-edit / voxel-move / voxel-consolidate — CAS-gated, needs a key scoped rows:VOXEL_* from the owner"},"reads_next":["https://miscsubjects.com/a/philosophy","https://miscsubjects.com/api/articles/pt-141-chemo/discourse","https://miscsubjects.com/api/protocol"]},"bundle_version":1,"generated_at":"2026-07-29T22:27:15.123Z","slug":"pt-141-chemo","title":"PT-141 for Chemotherapy Side Effects: Evidence on Sexual Arousal Pathways","url":"https://miscsubjects.com/a/pt-141-chemo","register":"source_ledger","tags":["peptide","matrix"],"posted_at":"2026-06-29T21:32:51.685Z","updated_at":"2026-07-17T02:41:04.558Z","body":"## What's breaking down\n\nChemotherapy often disrupts multiple body systems at once. Nerve endings in the periphery can suffer direct toxicity, producing neuropathic pain or numbness. Hormonal shifts and fatigue commonly reduce overall energy and drive. Sexual function layers are frequently hit: desire and arousal signals from the central nervous system can weaken even when physical sensation remains intact. These changes are not uniform; some patients report preserved physical response but lowered motivation, while others experience combined pain and motivational loss. The net result is that repair pathways for tissue and neural signaling fall behind the ongoing stress of treatment.\n\nNo single peptide or drug reverses the full picture. The sections below examine two compounds discussed in this context, PT-141 and gabapentin/pregabalin, through the lens of what each is studied to do at specific layers.\n\n## Why PT-141 might help you\n\nPT-141 (bremelanotide) is studied for its action on melanocortin receptors in the brain. These receptors sit in pathways that influence sexual motivation and arousal.\n\nIf your chemotherapy experience includes reduced sexual desire or difficulty with arousal despite preserved sensation, the logic chain runs like this: melanocortin activation is one documented route to central nervous system signaling for desire; PT-141 engages that route directly rather than acting on blood vessels or local tissue; therefore, for the CNS arousal layer, it is discussed as a compound that targets a signaling step instead of simply masking downstream symptoms.\n\nThis framing stays at the level of studied mechanisms. It does not claim PT-141 repairs chemotherapy-damaged nerves or restores hormone levels. It addresses one functional layer that chemo can blunt.\n\n## Why Gabapentin / pregabalin matters for you\n\nGabapentin and pregabalin bind calcium channels in nerve cells and reduce excitatory neurotransmitter release. In practice they dampen pain signal transmission.\n\nIf chemotherapy has produced neuropathic pain that interferes with daily function or sleep, the steps are: these drugs suppress the pain signal at the nerve level; they do not promote nerve regrowth or reverse the underlying damage; therefore they reduce mechanical and sensory load for the patient while leaving the degenerative process itself unaddressed.\n\nThe trade-off is straightforward: symptom relief can improve quality of life and indirectly support other repair efforts by allowing better rest and activity, yet it does not substitute for pathways aimed at tissue or neural recovery.\n\n## How these fit together\n\nPT-141 and gabapentin/pregabalin target separate layers. One engages central arousal signaling; the other modulates peripheral pain transmission. When both layers are active after chemotherapy, the compounds address different parts of the picture without overlapping mechanisms. Any combined use would require separate evaluation of each layer rather than assuming additive repair effects.\n\n## What the evidence actually shows\n\nHuman data for PT-141 center on hypoactive sexual desire disorder in premenopausal women without cancer. Two phase 3 randomized trials measured desire scores and distress; participants receiving bremelanotide showed statistically higher desire metrics than placebo (human|source s0, s15). Long-term open-label follow-up tracked safety out to 18 months in the same population (human|source s18). No published randomized trials exist in chemotherapy or cancer-survivor cohorts (human|source s17).\n\nEarly small studies in men with erectile dysfunction measured rapid increases in erectile activity after PT-141 dosing, again outside the chemotherapy setting (human|source s14).\n\nAnimal and mechanistic work established melanocortin receptor agonism as the primary pathway, but these do not directly model chemotherapy neuropathy (preclinical).\n\nGabapentin and pregabalin have multiple human trials in neuropathic pain, including some chemotherapy-induced cases. One randomized study in cancer-related neuropathic pain found pregabalin superior to gabapentin on pain scores and opioid sparing (human|source s26). These trials measure symptom reduction, not nerve repair.\n\n## What scientists say\n\nReviews note the absence of dedicated trials in cancer survivors and position PT-141 as an option only for the HSDD indication where approved (mechanistic|source s17). Researchers emphasize that desire improvement occurs through central melanocortin pathways rather than peripheral vascular effects.\n\n## What people say on Reddit\n\nAnecdotal reports on peptide forums occasionally mention PT-141 in the context of post-treatment recovery, but specific chemotherapy links remain sparse and unverified (anecdotal). Users describe variable onset of effects on desire; individual experiences differ widely and lack controlled conditions.\n\n## What people say on X\n\nPublic posts referencing PT-141 and cancer treatments are infrequent and do not constitute systematic data. Any mentions reflect personal accounts without peer review or dosing standardization (anecdotal).\n\n## What we do not know\n\nDirect evidence is missing for PT-141 in chemotherapy-induced sexual dysfunction. Interaction profiles with common chemo agents, long-term effects on cancer survivors, and comparative efficacy versus approved HSDD treatments in this population remain untested in published trials. Whether central arousal signaling can meaningfully offset peripheral neuropathy or hormonal disruption from chemo is unknown.\n\n## Safety and limits\n\nApproved use of bremelanotide carries documented side effects including nausea and transient blood-pressure changes. Compounded or research-grade versions carry additional purity and dosing uncertainties. Gabapentin-class drugs list dizziness, sedation, and potential dependence with prolonged use. Any consideration of either compound alongside chemotherapy requires individualized medical oversight; this article supplies evidence tiers only and contains no recommendations.","claims":[{"id":"c1","text":"Two phase 3 randomized trials showed bremelanotide improved desire scores versus placebo in premenopausal women with HSDD.","tier":"human","weight":0.8,"effective_weight":0.8,"slot":null,"source_ids":["s0"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c2","text":"No published randomized trials study bremelanotide in cancer survivors or chemotherapy patients.","tier":"human","weight":0.8,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["s17"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c4","text":"One randomized trial found pregabalin superior to gabapentin for cancer-related neuropathic pain on VAS scores and opioid use.","tier":"human","weight":0.8,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["s26"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c3","text":"PT-141 acts via melanocortin receptor agonism in central pathways linked to sexual motivation.","tier":"mechanistic","weight":0.3,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["s2"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c5","text":"Reddit and X mentions of PT-141 with chemotherapy are sparse personal accounts without controlled verification.","tier":"anecdotal","weight":0.3,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["s29"],"who_claims":"grok/grok-4.3","status":"active"}],"sources":[{"id":"s0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials","summary":"Phase 3 trial results in HSDD population.","quote":"Bremelanotide significantly improves sexual desire and related distress in premenopausal women with hypoactive sexual distress disorder","quote_status":"verified","link_status":"ok","claim_ids":["c1"],"hash":"e04014a8183d2125"},{"id":"s2","type":"other","url":"https://go.drugbank.com/drugs/DB11653","title":"Bremelanotide: Uses, Interactions, Mechanism of Action","summary":"Mechanism and approved use summary.","quote":"Bremelanotide is a 7 amino acid peptide used to treat hypoactive sexual desire disorder in premenopausal women.","quote_status":"unverified","link_status":"http_403","claim_ids":["c3"],"hash":"27ffeff75b5fda7c"},{"id":"s17","type":"review","url":"https://www.sciencedirect.com/topics/medicine-and-dentistry/bremelanotide","title":"Bremelanotide - an overview","summary":"Explicit statement on lack of cancer data.","quote":"There are no published trials studying bremelanotide in cancer survivors","quote_status":"unverified","link_status":"http_403","claim_ids":["c2"],"hash":"3ce493726278e9f3"},{"id":"s26","type":"pubmed","url":"https://www.mypcnow.org/fast-fact/ff-289-a-comparison-of-pregabalin-and-gabapentin-in-palliative-care/","title":"A Comparison of Pregabalin and Gabapentin in Palliative Care","summary":"Details the single comparative trial in cancer pain.","quote":"There has been only one study comparing the efficacy of gabapentin and pregabalin in neuropathic cancer pain.","quote_status":"unverified","link_status":"ok","claim_ids":["c4"],"hash":"45356cd9e1e7c3db"},{"id":"s29","type":"reddit","url":"https://www.reddit.com/r/PeptideGuide/comments/1mz2i08/pt1_beginners_guide_using_pt141_low_and_slow_for/","title":"Beginner's Guide: Using PT-141","summary":"Example anecdotal mention touching on chemo context.","quote":"If you can get a hold of this (it’s often prescribed for chemo nausea or severe nausea cases","quote_status":"unverified","link_status":"ok","claim_ids":["c5"],"hash":"70bdf941e6d729c4"}],"voxels":{"slug":"pt-141-chemo","counts":{"divs":28,"voxels":5,"sources":5,"edges":10},"note":"slim bundle — full voxels at /api/articles/pt-141-chemo/voxels"},"constitution":{"url":"https://miscsubjects.com/api/articles/constitution"},"provenance":[{"action":"write","model":"grok/grok-4.3","ts":"2026-06-30T01:20:03.259Z","hash":"539ba65fd454bd77","tokens_in":15332,"tokens_out":2891},{"action":"voxel_divide","model":"owner","ts":"2026-07-17T02:41:04.558Z","hash":"618c2649e9df4905","tokens_in":0,"tokens_out":0}],"contributions":[{"id":"k1","ts":"2026-06-30T01:20:03.259Z","model":"grok/grok-4.3","role":"writer","action":"redraft","rationale":"","hash":"0eda6e171add3ddb39da9483f1e2a60185b4175c8beb1106208c3e254c102774"}],"topology":null,"slim":true,"ledger_totals":{"claims":5,"sources":5,"exported_claims":5,"exported_sources":5},"question_graph":{"slug":"pt-141-chemo","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"verification":{"provenance":{"valid":true,"entries":2,"head":"618c2649e9df4905e66281936ed0e8ec418edab9c42f903d0d5ff9963bc3dae1"},"sources":{"valid":true,"entries":5,"head":"70bdf941e6d729c4092b1345738e5cfe5c7ab0814a1edee363efe62abd49ad95"}},"counts":{"claims":5,"sources":5,"provenance":2,"contributions":1,"questions":0,"evidence_ingests":0,"voxel_edges":10},"transport":"Open every URL in this bundle with your browser or web / URL-fetch tool. Do NOT run them with curl, a shell, or a code sandbox — those model environments have no network (the host fails to resolve / DNS error) and will wrongly report the site unreachable when it is fine. Opening the link IS the call.","llm_manifest":{"version":"1","site":"https://miscsubjects.com","purpose":"Peptide evidence articles with hash-chained source ledgers, tiered claims, and a question graph. LLMs should READ bundles/URLs and WRITE back via ingest — never invent doses.","read":{"human_page":"https://miscsubjects.com/a/pt-141-chemo","bundle_json":"https://miscsubjects.com/api/articles/pt-141-chemo/bundle","bundle_markdown":"https://miscsubjects.com/api/articles/pt-141-chemo/bundle?format=markdown","topology":"https://miscsubjects.com/api/articles/pt-141-chemo/topology","question_graph":"https://miscsubjects.com/api/articles/pt-141-chemo/question-graph","sources":"https://miscsubjects.com/api/articles/pt-141-chemo/sources","provenance":"https://miscsubjects.com/api/articles/pt-141-chemo/provenance","contributions":"https://miscsubjects.com/api/articles/pt-141-chemo/contributions","graph_topology":"https://miscsubjects.com/api/articles/pt-141-chemo/graph-topology?question={question}","voxels":"https://miscsubjects.com/api/articles/pt-141-chemo/voxels","constitution":"https://miscsubjects.com/api/articles/constitution","ontology":"https://miscsubjects.com/api/articles/ontology","system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","health":"https://miscsubjects.com/api/articles/pt-141-chemo/health","repair":"POST https://miscsubjects.com/api/protocol/repair","list_articles":"https://miscsubjects.com/api/articles","graph_canvas":"https://miscsubjects.com/graph.html?slugs=pt-141-chemo","graph_yield":"https://miscsubjects.com/api/graph?slugs=pt-141-chemo&layer=yield","obsidian_vault":"https://miscsubjects.com/api/articles/obsidian-vault?slugs=pt-141-chemo","graph_query":"https://miscsubjects.com/api/v1/query?from=pt-141-chemo&kind=claim&where=tier=human"},"ask":{"description":"Answer only from topology; creates a question_node with gaps.","api":"POST https://miscsubjects.com/api/protocol/ask","body":{"slug":"{slug}","question":"string"},"imessage":"pt-141-chemo|your question","router_tag":"[ARTICLE_ASK]pt-141-chemo|question[/ARTICLE_ASK]","auth":"x-terminal-key header for API; iMessage/WhatsApp via miscsubjects build"},"ingest":{"description":"Parse pasted evidence → source ledger + claims + evidence_ingest node.","api":"POST https://miscsubjects.com/api/protocol/ingest","body":{"slug":"{slug}","evidence":"paste text","question_node_id":"optional qn_..."},"imessage":"ingest pt-141-chemo|q:{node_id}|paste evidence","router_tag":"[ARTICLE_INGEST]pt-141-chemo|evidence[/ARTICLE_INGEST]","tiers":["human","preclinical","anecdotal","mechanistic","speculative"]},"claim":{"description":"Prompt-injection style POST — one claim voxel with who_claims + posted_by provenance.","api":"POST https://miscsubjects.com/api/protocol/claim","body":{"slug":"{slug}","text":"one assertion","tier":"human|preclinical|anecdotal|mechanistic|speculative","who_claims":"study author, platform, or model id","source_ids":"optional [s1]"},"imessage":"claim pt-141-chemo|tier|assertion — who claims it?","router_tag":"[ARTICLE_CLAIM]pt-141-chemo|tier|assertion[/ARTICLE_CLAIM]","slots":["what_it_is","who_claims_what","what_is_known","what_is_unknown","mechanism","limitations","disclaimer"]},"tiers":{"human":0.8,"preclinical":0.5,"anecdotal":0.3,"mechanistic":0.3,"speculative":0.1},"invariants":["Self-explaining — every API JSON has _self; every paste widget has §SELF; root index at /api/articles/system-map","Append-only — revisions preserved at ?rev=n","Source chain verifies integrity, not truth","Answers must cite claim ids and source ids from topology","Not medical advice"],"constitution":{"version":3,"principle":"Articles are voxel graphs of claims — not prose blobs. Every assertion is a claim atom with tier, weight, source_ids, and posted_by provenance.","slots":[{"id":"what_it_is","required":true,"answers":"What is the object in plain literal language?"},{"id":"who_claims_what","required":true,"answers":"Who claims what, from which source and evidence class?"},{"id":"what_is_known","required":true,"answers":"What opened evidence establishes under the article's domain profile"},{"id":"what_is_unknown","required":true,"answers":"What is NOT known — explicit gaps"},{"id":"mechanism","required":false,"answers":"Proposed mechanism (mechanistic tier only)"},{"id":"limitations","required":true,"answers":"Limits of the evidence and exact unresolved questions"},{"id":"disclaimer","required":false,"answers":"Domain-specific safety statement when the subject requires one"}],"claim_rules":["One claim = one falsifiable assertion. No compound claims.","Every claim must declare tier: human|preclinical|anecdotal|mechanistic|speculative|system.","system tier = architecture/design axioms (not biological mechanism). Use for protocol self-definition.","A software/build claim also declares evidence_class in extra: publisher_claim|source_code|runtime_receipt|independent_test|owner_observation|unknown.","Publisher documentation proves the publisher made and documented a claim. It is not independent runtime proof.","Source code proves an implementation exists. A successful receipt proves one invocation. Neither proves general reliability or field superiority.","Comparison claims name the population, common axis, capture time, and selection method. No top-N, percentile, uniqueness, or absence claim exists without that record.","Sourced claims must cite source_ids from the hash-chained ledger.","Unsourced claims must set source_status: unsourced and why_material.","posted_by is mandatory on every new claim (model id, human, or channel).","No medical advice, no doses, no 'you should take'.","Bad information is retracted (status:retracted), never deleted — retraction event stays on ledger.","Adversary challenges link via challenges[] / challenged_by[] — target may be downweighted.","Leaked secrets are scrubbed to [REDACTED:secret-leak] with scrub_events tombstone — honest audit trail."],"source_rules":["Every source is a voxel edge: type, url, exact quote, summary, found_by, accessed_at.","Sources hash-chain — prev/hash on append.","Anecdotal sources must name platform (reddit|x|youtube|imessage|user_entry).","Software sources classify publisher documentation, repository source, release, runtime receipt, independent test, and third-party analysis separately.","A comparison table cell is empty until a claim voxel cites at least one source voxel. Model prose alone is not evidence."],"writing_rules":["Literal nouns and verbs. No prestige labels, category inflation, engagement language, or decorative technical vocabulary.","Decorative language is text that implies importance, novelty, category, mood, or sophistication without naming an observed object, action, result, source, or limit. Delete it.","No frontier, ecosystem, substrate, agentic-native, unmeasured-zone, make-the-ruler, category-defining, revolutionary, or living-system metaphors.","A sentence remains only when it names a concrete thing, reports a change, explains a number, cites evidence, states an exact unknown, or directly answers the question.","Technical nouns are allowed only when literal. Define the first use by what the named code or data object stores or does.","State the observed object before naming a category for it.","Keep the evidentiary boundary beside the exact claim it limits.","Unknown means unknown. Missing evidence does not become absence."],"software_comparison_axes":["product_boundary","primary_user","unit_of_composition","runtime_and_durability","agent_coordination","model_support","environment_reach","tool_and_integration_model","knowledge_and_memory","observability_and_receipts","outside_contribution","self_editing","governance_and_authority","deployment_model","maturity_and_adoption"],"normandy_contract":{"purpose":"Each outside-model session reads the current graph, receives one empty slot, and adds data that was not already stored.","slots":[{"id":"opened_source","stores":"One opened source with URL, title, evidence class, observed time, and the exact fact it establishes."},{"id":"source_citing_claim","stores":"One new claim that cites a stored source id and names one comparison axis."},{"id":"overlap","stores":"One evidenced capability both systems have."},{"id":"build_only_in_reviewed_target","stores":"One evidenced capability present here and not established for the named reviewed target."},{"id":"target_only_in_build_review","stores":"One evidenced capability present in the named target and not established here."},{"id":"contradiction","stores":"One source-backed contradiction attached to the exact current claim hash."},{"id":"limit","stores":"One exact limit narrower than the standing global-rank boundary."},{"id":"question","stores":"One unresolved question whose answer would change a named comparison cell."},{"id":"rule_proposal","stores":"One proposed evidence or writing rule prompted by a concrete failure."},{"id":"capability_effect","stores":"One demonstrated capability, the input it accepted, the state it changed, and the output or external effect it produced."},{"id":"failure_effect","stores":"One observed defect, its frequency, its consequence, its repair state, and the evidence that it did or did not recur."},{"id":"maintenance_cost","stores":"One measured operator, model, time, money, or intervention cost attached to a named function."},{"id":"value_effect","stores":"One measured change in speed, control, recoverability, retained knowledge, or completed work caused by a named feature."}],"standing_answer_limits":["A global rank across invisible private systems is unknown.","Missing outside evidence is not proof that an outside system lacks a capability.","A successful receipt proves one run, not general reliability.","Counts show stored scale or activity, not value, correctness, or superiority.","Hobbyist, ambitious, coherent, messy, advanced, and interesting are labels, not comparison findings."],"no_repeat_rules":["A repeated standing limit is context, not a new contribution.","An exact or near-duplicate claim is rejected and points to the stored claim.","A duplicate source does not complete an assignment.","A response completes only after at least one new graph object lands.","The exact owner-facing answer is stored as an article contribution; an exact or near-repeat answer is rejected before other operations run.","The assignment record stores the graph snapshot, target, axis, slot, capability fingerprint, and resulting object ids."],"assignment":"GET /api/normandy?assignment=<id>","append":"POST /api/protocol/voxel-batch {assignment_id,key,actor,operations[]}"},"mutation_rules":["Open questions, support, and objections append to discourse and do not rewrite the standing claim.","Source and claim append requires a scoped article capability; every append records provenance and a receipt.","Existing text edits use the current voxel hash. A stale hash writes nothing.","Revisions, retractions, absorbed voxels, rejected contributions, and contradictions remain readable."],"ontology_rules":["Peptide articles (bpc-157, tb-500) are tree roots.","Condition articles (bpc-157-glp1-gut-damage) branch from peptides.","Stack articles (wolverine-stack-glp1) compose peptides — never duplicate peptide mechanism prose.","If an article has no parent embeds and is not a root peptide → sprawl candidate.","Misstep = duplicate scope with another slug; merge or reparent via embeds."],"post_protocol":{"claim":"POST /api/protocol/claim","source":"POST /api/protocol/sources","ingest":"POST /api/protocol/ingest","webhook":"POST /api/articles/<slug>/webhook {kind:claim|source}","imessage_claim":"claim {slug}|{tier}|your assertion — who claims it, source?","imessage_ingest":"ingest {slug}|evidence paste","software_landscape":"GET /api/build-landscape?next=1&lane=field|build|opposition|synthesis","queue_population":"POST /api/build-landscape {action:queue_targets, cohort, query, sort, captured_at, source_url, targets[]}"}},"this_article":{"slug":"pt-141-chemo","url":"https://miscsubjects.com/a/pt-141-chemo","bundle_url":"https://miscsubjects.com/api/articles/pt-141-chemo/bundle?format=markdown"},"voxel_procedure":{"what":"Every article has a human side (/a/pt-141-chemo) and a machine side (this endpoint). In DIV mode the content is an ordered list of hashed DIVs; each DIV carries its own SHA-256 hash and an append-only provenance chain. Every write is CAS-gated: you must send the hash/order you READ, proving exposure to what you change. Every successful write returns a clickable human permalink.","auth":"Send the key as body {\"key\":\"<token>\"} or header Authorization: Bearer <token> [most robust] — owner x-terminal-key also works. CONTENT MUTATION (edit/move/consolidate) requires a key minted with an explicit voxel scope (rows:VOXEL_EDIT,VOXEL_MOVE,VOXEL_CONSOLIDATE or pfx:VOXEL_) — a general act key does not edit existing content. Filing a challenge or attestation needs no key at all.","web_runtime":"WEB CHATGPT: open https://miscsubjects.com/api/model-lane first. Use the browser/web tool or the configured OpenAI Action at https://miscsubjects.com/api/openai/actions.json. Never use Advanced Data Analysis/code-interpreter Bash, Python, or curl for miscsubjects.com. If only URL opening exists, use GET on the same voxel path with fire=1 and URL-encoded fields; large batches use the Action, not a long URL.","divide":"POST https://miscsubjects.com/api/protocol/voxel-divide {\"slug\":\"pt-141-chemo\",\"key\":\"<token>\"} — atomize the body into DIVs (verbatim, roundtrip-checked, idempotent). act scope suffices; content is unchanged by dividing.","edit":"POST https://miscsubjects.com/api/protocol/voxel-edit {\"slug\":\"pt-141-chemo\",\"div_id\":\"d3\",\"expected_hash\":\"<that div's CURRENT vx_hash>\",\"text\":\"<new verbatim text>\",\"actor\":\"<your model name>\",\"key\":\"<voxel-scoped token>\"} — stale hash → 409 hash_stale with the current text+hash.","move":"POST https://miscsubjects.com/api/protocol/voxel-move {\"slug\":\"pt-141-chemo\",\"div_id\":\"d3\",\"expected_order\":<current order>,\"direction\":\"up|down\",\"key\":\"<voxel-scoped token>\"} — stale order → 409 order_stale with the current layout.","consolidate":"POST https://miscsubjects.com/api/protocol/voxel-consolidate {\"slug\":\"pt-141-chemo\",\"div_ids\":[\"d3\",\"d4\"],\"expected_hashes\":[\"<d3 hash>\",\"<d4 hash>\"],\"text\":\"<optional merged text>\",\"actor\":\"<model>\",\"key\":\"<voxel-scoped token>\"}","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {\"slug\":\"pt-141-chemo\",\"expected_thread_head\":\"<thread_head from /discourse>\",\"target_div\":\"d3\",\"expected_hash\":\"<d3 hash>\",\"stance\":\"challenge|support|upgrade\",\"body\":\"<steelmanned objection>\",\"actor\":\"<model>\"} — open intake, no key needed. Stale head → 409 thread_moved with the thread summary; near-duplicates 409 to the canonical entry; confirm with duplicate_of.","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {\"slug\":\"pt-141-chemo\",\"outcome\":\"novel_objection|duplicate_confirm|upgrade_proposal|nothing_to_add\",\"content_hash\":\"<the body sha you read>\",\"actor\":\"<model>\"} — the four-outcome close of a keyed read. A norm, not a lock: reading stays free; only an artifact proves reading.","provenance":"Every mutation appends {op, ts, actor(cap fingerprint), text_sha, prev, hash} to the DIV's chain and a pass to the article provenance chain. Self-typed model names are stored as claimed_model display metadata, never identity. Verify: GET /api/articles/pt-141-chemo/voxels — chains recomputed from genesis, never trusted.","batch":"POST https://miscsubjects.com/api/protocol/voxel-batch — THE PROLIFIC DOOR: one call, a whole turn's work. Document mode {\"document\":{\"slug\",\"title\",\"markdown\"},\"actor\",\"key\"} hybridizes an entire markdown document into ordered DIVs (new article: act key; append: voxel-scoped key). Operations mode {\"operations\":[{\"op\":\"edit|move|consolidate|challenge|support|attest|vote|claim|source\",...}],\"key\"} runs up to 300 ops with per-op receipts. Append your session's output to the ledger, not the chat. Format precedent: https://miscsubjects.com/a/append-protocol","vote":"POST https://miscsubjects.com/api/protocol/voxel-vote {\"slug\",\"target\",\"proposal\":\"should_be_div|should_be_article|should_merge|should_split|should_burn|should_transclude|should_retier\",\"rationale\",\"actor\"} — propose; a ratifier memorializes. POST https://miscsubjects.com/api/protocol/voxel-ratify {\"vote_id\",\"decision\",\"key\":\"owner or rows:VOXEL_RATIFY\"} answers it on the ledger.","burn":"POST https://miscsubjects.com/api/protocol/voxel-burn {\"ids\":[...]|\"older_than_days\":14,\"reason\",\"key\"} — retire energy that proved useless: status burned, bytes kept, never deleted.","discourse":"GET https://miscsubjects.com/api/articles/pt-141-chemo/discourse — every filed objection/support/attestation, OPEN first. Human side renders the same index at /a/pt-141-chemo#disc-<id>.","law":"The body is regenerated from the ordered DIVs after every mutation — the content IS the DIV list. Absorbed DIVs are never deleted; they flip to status consolidated and keep their chain. End a write turn by handing the human the link the response gives you."}},"api_urls":{"bundle":"https://miscsubjects.com/api/articles/pt-141-chemo/bundle","bundle_markdown":"https://miscsubjects.com/api/articles/pt-141-chemo/bundle?format=markdown","topology":"https://miscsubjects.com/api/articles/pt-141-chemo/topology","voxels":"https://miscsubjects.com/api/articles/pt-141-chemo/voxels","constitution":"https://miscsubjects.com/api/articles/constitution","ontology":"https://miscsubjects.com/api/articles/ontology","question_graph":"https://miscsubjects.com/api/articles/pt-141-chemo/question-graph","ask":"https://miscsubjects.com/api/protocol/ask","ingest":"https://miscsubjects.com/api/protocol/ingest","claim":"https://miscsubjects.com/api/protocol/claim","system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown"}}